Literature DB >> 33432034

Defining a therapeutic range for regeneration of ischemic myocardium via shock waves.

Leo Pölzl1,2, Felix Nägele1, Jakob Hirsch1, Michael Graber1, Daniela Lobenwein1,2, Elke Kirchmair1, Rosalie Huber1, Christian Dorfmüller3, Sophia Lechner1, Georg Schäfer4, Martin Hermann5, Helga Fritsch2, Ivan Tancevski6, Michael Grimm1, Johannes Holfeld1, Can Gollmann-Tepeköylü7.   

Abstract

Shockwave therapy (SWT) represents a promising regenerative treatment option for patients with ischemic cardiomyopathy. Although no side-effects have been described upon SWT, potential cellular damage at therapeutic energies has not been addressed so far. In this work, we aimed to define a therapeutic range for shock wave application for myocardial regeneration. We could demonstrate that SWT does not induce cellular damage beneath energy levels of 0.27 mJ/mm2 total flux density. Endothelial cell proliferation, angiogenic gene expression and phosphorylation of AKT and ERK are enhanced in a dose dependent manner until 0.15 mJ/mm2 energy flux density. SWT induces regeneration of ischemic muscle in vivo via expression of angiogenic gene expression, enhanced neovascularization and improved limb perfusion in a dose-dependent manner. Therefore, we provide evidence for a dose-dependent induction of angiogenesis after SWT, as well as the absence of cellular damage upon SWT within the therapeutic range. These data define for the first time a therapeutic range of SWT, a promising regenerative treatment option for ischemic cardiomyopathy.

Entities:  

Year:  2021        PMID: 33432034      PMCID: PMC7801389          DOI: 10.1038/s41598-020-79776-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

Review 1.  Understanding the biology of angiogenesis: review of the most important molecular mechanisms.

Authors:  Zaher K Otrock; Rami A R Mahfouz; Jawad A Makarem; Ali I Shamseddine
Journal:  Blood Cells Mol Dis       Date:  2007-06-06       Impact factor: 3.039

Review 2.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

3.  Epicardial shock-wave therapy improves ventricular function in a porcine model of ischaemic heart disease.

Authors:  Johannes Holfeld; Daniel Zimpfer; Karin Albrecht-Schgoer; Alexander Stojadinovic; Patrick Paulus; Julia Dumfarth; Anita Thomas; Daniela Lobenwein; Can Tepeköylü; Raphael Rosenhek; Wolfgang Schaden; Rudolf Kirchmair; Seyedhossein Aharinejad; Michael Grimm
Journal:  J Tissue Eng Regen Med       Date:  2014-05-19       Impact factor: 3.963

4.  Molecular mechanisms of the angiogenic effects of low-energy shock wave therapy: roles of mechanotransduction.

Authors:  Kazuaki Hatanaka; Kenta Ito; Tomohiko Shindo; Yuta Kagaya; Tsuyoshi Ogata; Kumiko Eguchi; Ryo Kurosawa; Hiroaki Shimokawa
Journal:  Am J Physiol Cell Physiol       Date:  2016-07-13       Impact factor: 4.249

5.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

6.  Angiogenic response to extracorporeal shock wave treatment in murine skin isografts.

Authors:  Alexander Stojadinovic; Eric A Elster; Khairul Anam; Douglas Tadaki; Mihret Amare; Stephen Zins; Thomas A Davis
Journal:  Angiogenesis       Date:  2008-11-09       Impact factor: 9.596

7.  Toll-like receptor 3 signalling mediates angiogenic response upon shock wave treatment of ischaemic muscle.

Authors:  Johannes Holfeld; Can Tepeköylü; Christin Reissig; Daniela Lobenwein; Bertram Scheller; Elke Kirchmair; Radoslaw Kozaryn; Karin Albrecht-Schgoer; Christoph Krapf; Karin Zins; Anja Urbschat; Kai Zacharowski; Michael Grimm; Rudolf Kirchmair; Patrick Paulus
Journal:  Cardiovasc Res       Date:  2015-12-16       Impact factor: 10.787

8.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

9.  Shockwaves prevent from heart failure after acute myocardial ischaemia via RNA/protein complexes.

Authors:  Can Tepeköylü; Uwe Primessnig; Leo Pölzl; Michael Graber; Daniela Lobenwein; Felix Nägele; Elke Kirchmair; Elisabeth Pechriggl; Michael Grimm; Johannes Holfeld
Journal:  J Cell Mol Med       Date:  2016-12-20       Impact factor: 5.310

10.  In-vitro cell treatment with focused shockwaves-influence of the experimental setup on the sound field and biological reaction.

Authors:  Kristin Dietz-Laursonn; Rainer Beckmann; Siegfried Ginter; Klaus Radermacher; Matías de la Fuente
Journal:  J Ther Ultrasound       Date:  2016-03-29
View more
  1 in total

Review 1.  Cardiac Shockwave Therapy - A Novel Therapy for Ischemic Cardiomyopathy?

Authors:  Michael Graber; Felix Nägele; Jakob Hirsch; Leo Pölzl; Victor Schweiger; Sophia Lechner; Michael Grimm; John P Cooke; Can Gollmann-Tepeköylü; Johannes Holfeld
Journal:  Front Cardiovasc Med       Date:  2022-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.